^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

tagitanlimab (HBM9167)

i
Other names: HBM9167, A 167, KL A167, KLA167, A167, KL-A167, A-167, HBM 9167, HBM-9167
Associations
Company:
Harbour BioMed, Sichuan Kelun Pharma
Drug class:
PD-L1 inhibitor
Related drugs:
Associations
7ms
Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study. (ASCO 2024)
Background: Sacituzumab Tirumotecan (SKB264/MK-2870)is a TROP2 ADC developed with novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor. SKB264 in combination with KL-A167 demonstrated promising efficacy results in treatment naive advanced NSCLC with manageable safety profile. SKB264 Q2W was recommended for further investigation. A Phase 3 study of SKB264 Q2W plus pembrolizumab vs pembrolizumab in 1L metastatic NSCLC with PD-L1 TPS ≥ 50% (NCT06170788) is ongoing.
Combination therapy • P2 data • Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • sacituzumab tirumotecan (MK-2870) • Camtobell (belotecan) • tagitanlimab (HBM9167)
11ms
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov)
P2, N=110, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Aug 2023 --> Aug 2024
Enrollment open • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • EGFR wild-type • ALK fusion • ALK negative
|
cisplatin • carboplatin • sacituzumab tirumotecan (MK-2870) • tagitanlimab (HBM9167)
1year
Trial completion
|
tagitanlimab (HBM9167)
1year
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov)
P3, N=295, Active, not recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
cisplatin • gemcitabine • tagitanlimab (HBM9167)
1year
SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer (clinicaltrials.gov)
P2, N=175, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | N=95 --> 175 | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
sacituzumab tirumotecan (MK-2870) • tagitanlimab (HBM9167)
over2years
New P2 trial • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • EGFR wild-type • ALK fusion • ALK negative
|
cisplatin • carboplatin • sacituzumab tirumotecan (MK-2870) • tagitanlimab (HBM9167)